Presentation 1209-083: Soluble FMS-Like Tyrosine Kinase-1 (Sflt-1) is Associated with Subclinical and Clinical ASCVD: The Dallas Heart Study
Publication Title
Journal of the American College of Cardiology
Document Type
Presentation
Publication Date
3-2020
Keywords
washington; spokane
Abstract
Background
Soluble Fms-like tyrosine kinase-1 (sFlt-1) plays a role in angiogenesis, atherogenesis, and preeclampsia but associations with subclinical atherosclerosis and clinical events in healthy adults are unknown.
Methods
Participants from the Dallas Heart Study with sFlt-1 measured were included (n=3932). Abdominal aortic atherosclerosis was measured by MRI and coronary artery calcium (CAC) by CT. The cohort was followed for subsequent atherosclerotic cardiovascular disease (ASCVD) events (CV death, MI, stroke, revascularization). Multivariable linear and logistic regression and Cox regression analyses were performed for sFlt-1, analyzed by quartile (Q4 vs. Q1), adjusting for demographics and traditional risk factors.
Results
sFlt-1 levels were higher in older individuals, males, and African Americans and tracked with traditional cardiac risk factors. sFlt-1 was significantly associated with aortic wall thickness and plaque area (p<0.05). sFlt-1 independently associated with prevalent aortic plaque [OR 1.32, 1.02–1.72] but not CAC. There were 336 ASCVD events over 12 years of follow-up. Higher sFlt-1 levels associated with increased ASCVD events in unadjusted (16.7% vs. 8.8%, p<0.001) (Figure) and adjusted analyses [HR 1.58, 1.14–2.18]. Findings were unchanged when excluding those with prior ASCVD. Download FigureDownload PowerPoint
Conclusion
sFlt-1 is associated with subclinical aortic atherosclerosis and clinical ASCVD events. Future studies are warranted on sFlt-1 as a potential therapeutic target.
Footnotes
Poster Contributions
Posters Hall_Hall A
Saturday, March 28, 2020, 3:45 p.m.-4:30 p.m.
Session Title: Prevention: Clinical 3
Abstract Category: 32. Prevention: Clinical
Presentation Number: 1209-083
Area of Special Interest
Cardiovascular (Heart)
Specialty/Research Institute
Cardiology
